Tourmaline Bio Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Sandeep Kulkarni
Chief executive officer
US$848.3k
Total compensation
CEO salary percentage | 68.97% |
CEO tenure | no data |
CEO ownership | 2.9% |
Management average tenure | 1.8yrs |
Board average tenure | less than a year |
Recent management updates
Recent updates
Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition
May 20We're Not Very Worried About Tourmaline Bio's (NASDAQ:TRML) Cash Burn Rate
Apr 19Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting
Oct 13Tourmaline Bio: Sinking On Rival's Stodgy Data - I'm Slightly Bearish
Mar 22Tourmaline Bio: Time For A Pause
Jan 18CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Mar 31 2025 | n/a | n/a | -US$83m |
Dec 31 2024 | US$848k | US$585k | -US$73m |
Sep 30 2024 | n/a | n/a | -US$64m |
Jun 30 2024 | n/a | n/a | -US$49m |
Mar 31 2024 | n/a | n/a | -US$48m |
Dec 31 2023 | US$3m | US$114k | -US$42m |
Compensation vs Market: Sandeep's total compensation ($USD848.25K) is below average for companies of similar size in the US market ($USD2.53M).
Compensation vs Earnings: Sandeep's compensation has been consistent with company performance over the past year.
CEO
Sandeep Kulkarni (43 yo)
Dr. Sandeep C. Kulkarni, M.D. was Chief Operating Officer of Immunovant, Inc. He serves as Co-Founder, CEO and Director at Tourmaline Bio, Inc. From July to October 2018, he served as Vice President, Speci...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | no data | US$848.25k | 2.87% $ 13.9m | |
CFO & Treasurer | 1.8yrs | US$1.37m | 0% $ 0 | |
Chief Business Officer | no data | US$582.25k | 0.27% $ 1.3m | |
Chief Technology Officer | no data | no data | no data | |
Vice President of People | no data | no data | no data | |
Chief Regulatory Officer | no data | US$886.62k | 0.23% $ 1.1m | |
Senior VP & Head of Quality | no data | no data | no data | |
Senior VP and Head of Commercial & Business Development | 1.8yrs | no data | no data | |
Senior Vice President of Medical Research | no data | no data | no data | |
VP & TA Head of Ophthalmology | 1.5yrs | no data | no data | |
VP & Head of Medical Affairs | no data | no data | no data | |
VP & Head of Pharmacovigilance | no data | no data | no data |
Experienced Management: TRML's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | no data | US$848.25k | 2.87% $ 13.9m | |
Independent Director | no data | US$152.33k | 0.0020% $ 9.8k | |
Independent Chairman | 1.6yrs | US$230.13k | 0% $ 0 | |
Independent Director | no data | US$154.33k | 3.79% $ 18.4m | |
Independent Director | no data | US$157.83k | 0.0020% $ 9.8k | |
Chairman of Cardiovascular Scientific Advisory Board | less than a year | no data | no data | |
Independent Director | no data | US$154.83k | 0.18% $ 856.1k | |
Member of Cardiovascular Scientific Advisory Board | less than a year | no data | no data | |
Independent Director | no data | US$145.38k | 0.33% $ 1.6m | |
Member of Cardiovascular Scientific Advisory Board | less than a year | no data | no data | |
Member of Cardiovascular Scientific Advisory Board | less than a year | no data | no data | |
Member of Cardiovascular Scientific Advisory Board | less than a year | no data | no data |
Experienced Board: TRML's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/07/23 12:25 |
End of Day Share Price | 2025/07/23 00:00 |
Earnings | 2025/03/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tourmaline Bio, Inc. is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Konstantinos Biliouris | BMO Capital Markets Equity Research |
Etzer Darout | BMO Capital Markets Equity Research |
Joshua Schimmer | Cantor Fitzgerald & Co. |